Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Keywords/Phrases:  monoclonal antibody conjugate
Results 1-25 of 1710 for your search:
Start Over
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: XMT-1522-1, NCI-2017-00221, NCT02952729
Chimeric Fibril-Reactive Monoclonal Antibody 111F4 in Treating Patients with Relapsed or Refractory Amyloid Light-Chain Amyloidosis
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and over
Trial IDs: AAAM5108, NCI-2014-01515, IRB-AAAM5108, NCT02245867
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 99
Trial IDs: M15-394, NCI-2016-00469, 2015-001645-84, NCT02565758
Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: M14-467, NCI-2015-01096, 2014-002609-39, NCT02462525
A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: M14-237, NCI-2014-00926, 2014-003154-14, NCT02099058
Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: EC1456-01, NCI-2016-00552, NCT01999738
A Safety Study of SGN-LIV1A in Breast Cancer Patients
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SGNLVA-001, NCI-2013-02245, NCT01969643
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CDX011-05, NCI-2015-00448, NCT02302339
Glembatumumab Vedotin in Treating Patients with Metastatic or Locally Recurrent Uveal Melanoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9855, NCI-2015-00159, NCI9855, NCT02363283
Brentuximab Vedotin Maintenance after Donor Stem Cell Transplant in Treating Patients with Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 65
Trial IDs: 2013-0351, NCI-2014-01593, NCT02169505
Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PrE0504, NCI-2016-00523, CDX011-54, NCT02713828
Conjugated Estrogens/Bazedoxifene in Treating Patients with Ductal Carcinoma in Situ Undergoing Surgery
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: NU 15B06, NCI-2016-00066, STU00202100, NCT02694809
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: GEN702, NCI-2015-01770, NCT02552121
HuMax-AXL-ADC Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: GCT1021-01, NCI-2017-00143, NCT02988817
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29365, NCI-2015-00293, 2014-001361-28, NCT02257567
ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AGS15E-13-1, NCI-2013-02093, NCT01963052
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 and over
Trial IDs: ADCT-402-102, NCI-2016-00226, NCT02669264
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX014-01, NCI-2016-01448, NCT02837991
Brentuximab Vedotin, Bendamustine Hydrochloride, and Rituximab in Treating Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 1507953455, NCI-2015-01468, T502a, NCT02623920
The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: NEOD001-CL002, NCI-2015-00566, NCT02312206
A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SGN19B-001, NCI-2016-00414, NCT02702141
Rituximab and Brentuximab Vedotin with Deferred Bone Marrow Transplant in Treating Patients with Hodgkin Lymphoma
Status: Active
Phase: No phase specified
Type: Treatment
Age: 16 and over
Trial IDs: J1354, NCI-2014-02618, NCT01900496
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NEOD001-201, NCI-2016-00255, NCT02632786
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15383, NCI-2015-01621, I7O-MC-JOBA, NCT02529553
Start Over